Rabies immunoglobulin
Brand names: HyperRAB, Imogam
Rabies immunoglobulin is a preparation of antibodies against rabies virus used as part of post-exposure prophylaxis to provide immediate passive immunity following a high-risk rabies exposure in previously unvaccinated individuals.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It supplies ready-made neutralising antibodies that bind and inactivate rabies virus at the wound site during the interval before an active immune response to vaccine develops.
Prescribing in practice
- As much of the dose as possible should be infiltrated into and around the wound, with any remainder given intramuscularly at a site distant from the vaccine to avoid neutralising the vaccine response.
- It is given together with, but never mixed in the same syringe as, rabies vaccine as part of post-exposure prophylaxis.
- It is indicated only for unimmunised (or incompletely immunised) people with a significant exposure; those previously fully vaccinated need vaccine boosters rather than immunoglobulin, as advised by specialist services.
Monitoring
Observe for immediate hypersensitivity reactions after administration; no routine laboratory monitoring is required.
Counselling the patient
- This injection gives immediate protection while the vaccine course builds your own immunity.
- Thorough wound cleaning and completing the full vaccine schedule are essential.
- Seek urgent specialist advice without delay after any possible rabies exposure.
Evidence & guidelines
Combined rabies immunoglobulin and vaccine for post-exposure prophylaxis is recommended by WHO and UK Health Security Agency guidance for high-risk exposures.
Reference: UKHSA Green Book Ch.27; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023